Urolithin A: what this postbiotic compound means for cellular aging

In longevity science, most molecules are discovered in a laboratory and take decades - if they get there at all - to produce meaningful human data. Urolithin A is different. It has accumulated over fifteen years of research, multiple randomized controlled trials, and publications in journals including Nature Aging, Cell Reports Medicine, and iScience. In 2025 and 2026, the volume and quality of that research accelerated further. The result is a compound that has earned its place in serious conversations about how aging happens at the cellular level - and what, if anything, can be done about it.

What Urolithin A is - and where it comes from

Urolithin A is not found directly in food. It is a postbiotic metabolite, meaning it is produced by gut bacteria when they process specific plant compounds. The precursors are ellagitannins, polyphenols present in foods such as pomegranates, walnuts, and certain berries. After ellagitannins reach the colon, specific bacteria - primarily Gordonibacter urolithinfaciens and Ellagibacter isourolithinifaciens - convert them into urolithins, of which Urolithin A is the primary bioactive form.

This metabolic pathway introduces an important complication: individual capacity to produce Urolithin A varies substantially depending on gut microbiome composition. Studies suggest that roughly 30–40% of people are non-producers or low-producers, regardless of dietary intake. This is one reason why direct oral supplementation with Urolithin A, rather than relying on food sources, has become the focus of clinical research. It bypasses microbiome variability and delivers the compound systemically at measurable concentrations.

The mechanism: mitophagy and mitochondrial quality control

The primary reason Urolithin A is relevant to aging biology is its ability to activate mitophagy - the selective autophagy pathway responsible for clearing damaged or dysfunctional mitochondria from the cell. Mitophagy is not a general cleanup process. It is a highly regulated quality control mechanism, dependent on the PINK1/Parkin pathway, through which cells identify mitochondria that have lost membrane potential and tag them for lysosomal degradation.

With age, this system slows. Dysfunctional mitochondria accumulate, particularly in post-mitotic tissues such as skeletal muscle, cardiac muscle, and neurons. The result is a progressive bioenergetic decline, increased reactive oxygen species production, and a state of chronic low-grade inflammation driven in part by the release of damaged mitochondrial DNA into the cytoplasm - which the innate immune system reads as a danger signal.

Urolithin A appears to counteract this by upregulating PINK1/Parkin-mediated mitophagy flux, increasing lysosomal activity, and supporting mitochondrial biogenesis through PGC-1α - effectively both accelerating the clearance of old mitochondria and stimulating the production of new ones. This was demonstrated in human skeletal muscle for the first time in the ATLAS trial (Amazentis SA, 2022), where skeletal muscle biopsies from participants taking Urolithin A showed proteomically confirmed upregulation of mitophagy pathways and mitochondrial metabolism pathways, compared to placebo.

Clinical trial evidence: muscle

The ATLAS trial (NCT03464500), a randomized, double-blind, placebo-controlled study published in Cell Reports Medicine (Singh et al., 2022), enrolled 88 overweight, untrained, middle-aged adults who received either placebo or Urolithin A at 500 mg or 1,000 mg per day for four months. At the end of the intervention, participants receiving Urolithin A showed approximately 12% improvement in hamstring muscle strength at both doses compared to placebo (p = 0.027 and p = 0.029 respectively). The 1,000 mg group also demonstrated significant within-group improvements in peak VO₂ — a measure of aerobic capacity — alongside reductions in plasma acylcarnitines and C-reactive protein, indicating improved mitochondrial efficiency and reduced systemic inflammation. Skeletal muscle biopsies confirmed this was not a peripheral effect: there were direct, tissue-level changes in mitochondrial protein expression.

An earlier Phase 1 randomized controlled trial published in JAMA Network Open (Andreux et al., 2019), involving 60 healthy older adults aged 65–90, established the safety and tolerability profile of Urolithin A, and confirmed that oral supplementation produced measurable increases in plasma acylcarnitines — biomarkers associated with mitochondrial fatty acid oxidation — at doses of 500 mg and 1,000 mg. That foundational trial was the first to demonstrate that Urolithin A could be safely delivered orally and produce mitochondrial biomarker changes in humans.

Clinical trial evidence: immune aging

One of the most significant studies published in this area appeared in Nature Aging in late 2025. The MitoIMMUNE trial (Denk et al., 2025, NCT05735886), conducted in collaboration with the Buck Institute for Research on Aging and the Georg-Speyer-Haus Institute, enrolled 50 healthy adults aged 45 to 70 in a randomized, double-blind, placebo-controlled design. Participants received 1,000 mg of Urolithin A or placebo daily for 28 days.

The primary outcomes focused on peripheral T cell phenotypes and immune metabolic function. Urolithin A significantly expanded naïve CD8+ T cells - the less differentiated, more proliferative immune cells that decline with age - with a treatment difference of 0.50 percentage points (95% CI: 0.16 to 0.83; p = 0.0437). Critically, these cells displayed reduced markers of terminal exhaustion. Immune cell fatty acid oxidation capacity increased significantly (treatment difference: 14.72 percentage points; 95% CI: 6.46 to 22.99; p = 0.0061), indicating a metabolic shift away from glycolysis toward mitochondria-dependent energy pathways. Natural killer cells and monocyte phagocytic function also improved. Gene expression analysis across multiple immune cell types showed widespread changes consistent with a more youthful immune metabolic profile.

This matters because immune aging - sometimes called immunosenescence - is not simply a loss of immune function. Dysfunctional immune cells contribute to the chronic inflammatory environment that accelerates tissue aging across multiple organs. Interventions that improve mitochondrial quality in immune cells may therefore have broader systemic relevance than the immune outcomes alone suggest.

Cardiovascular evidence: preclinical, but mechanistically grounded

A 2025 paper published in iScience (Ryu et al., 2025) examined Urolithin A's effects on cardiac mitochondrial function. The study identified significant downregulation of mitophagy-related genes - including PINK1, OPA1, and OPTN1 - in aged human cardiomyocytes. In a mouse model of natural aging and a rat model of heart failure with reduced ejection fraction (HFrEF), Urolithin A restored mitochondrial ultrastructure, improved ejection fraction, and reduced markers of mitochondrial fragmentation. A companion human analysis in the paper also found that 500 mg of Urolithin A daily for four months improved plasma biomarkers associated with cardiometabolic health. These are preclinical findings, and cardiovascular outcomes have not been studied in dedicated human trials - but the mechanistic basis is clear enough that several trials are now being planned.

What the research does not yet show

As with all compounds at this stage of clinical research, important limitations apply. Most human trials have used Mitopure, a specific pharmaceutical-grade form of Urolithin A produced by Amazentis SA, which may not be directly comparable to all commercially available supplements. The longest randomized trial to date is four months. The cardiovascular data is primarily preclinical. A 650-participant brain health trial is currently underway and expected to report results in 2026 - this will be the largest clinical study on Urolithin A conducted to date, and its findings will significantly shape how the field interprets the broader scope of this compound.

It is also worth noting that while Urolithin A's mechanism is well-characterized, the dose-response relationship across different tissues, the optimal supplementation duration, and the effect in people with existing conditions remain areas of active investigation.

Where L Cell's Urolithin A fits

L Cell's Urolithin A is formulated to deliver the compound at clinically studied doses, matching the range used in the ATLAS and MitoIMMUNE trials. The compound is relevant across multiple overlapping L Cell categories: autophagy modulation, ATP support, and mitochondrial health - reflecting the same breadth of action that has made it one of the most-studied molecules in contemporary aging biology.

For people who cannot reliably produce Urolithin A from food due to microbiome variability - which includes the majority of the population - supplementation provides a direct route to the mitochondrial quality control effects that the research has now demonstrated in muscle, immune, and cardiac tissue.

Scientific sources

• Andreux PA et al. (2019). The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. JAMA Network Open.
• Singh A et al. (2022). Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. Cell Reports Medicine.
• Denk D et al. (2025). Effect of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trial. Nature Aging.
• Ryu D et al. (2025). Urolithin A provides cardioprotection and mitochondrial quality enhancement preclinically and improves human cardiovascular health biomarkers. iScience.
• Kuerec AH et al. (2024). Targeting aging with urolithin A in humans: a systematic review. Ageing Research Reviews.